Stay updated on Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous Revision: v3.5.3. This indicates a newer revision of the page metadata associated with an updated release of the document.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedIn the Taiwan locations list, the Taoyuan District entry was removed and replaced with Taoyuan, Taiwan, 333, preserving the same site code. This reflects a standardization of the city name in the study's locations.SummaryDifference0.0%

- Check39 days agoChange DetectedThe page’s footer revision/version number was updated from v3.5.2 to v3.5.3, reflecting a minor technical update with no change to the displayed study record content.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check61 days agoChange DetectedThe study location entry was updated from Padua, Veneto, Italy, 35128 to Padova, Veneto, Italy, 35128.SummaryDifference0.0%

- Check75 days agoChange DetectedAdded Hepatocellular carcinoma as the condition, included the Genetic and Rare Diseases Information Center as a resource, and updated the location entry from Napoli to Naples, Campania, Italy (80131) with revision to v3.5.0.SummaryDifference0.1%

Stay in the know with updates to Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page.